Kacar M, Al-Hakim A, Savic S
BioDrugs. 2024; 39(1):103-130.
PMID: 39680306
DOI: 10.1007/s40259-024-00696-9.
Kumar A, Soumerai J, Soumerai J, Abramson J, Barnes J, Caron P
Blood. 2024; 145(5):497-507.
PMID: 39437708
PMC: 11826521.
DOI: 10.1182/blood.2024025563.
Kim C, Park J, Choi Y, Jun H, Chung J, Park T
Front Endocrinol (Lausanne). 2024; 15:1420024.
PMID: 39280007
PMC: 11392736.
DOI: 10.3389/fendo.2024.1420024.
Alsuhebany N, Pan C, Holovac E, Do B, McBride A
Blood Lymphat Cancer. 2023; 13:67-76.
PMID: 38034984
PMC: 10683511.
DOI: 10.2147/BLCTT.S426588.
Tang P, Bao S, Xiao Z, Xie W, Wu X, Ge H
BMC Chem. 2023; 17(1):107.
PMID: 37649082
PMC: 10469817.
DOI: 10.1186/s13065-023-01017-x.
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Fisher J, Doyle A, Graham L, Sonar S, Sale B, Henderson I
Leukemia. 2023; 37(10):2036-2049.
PMID: 37528310
PMC: 10539165.
DOI: 10.1038/s41375-023-01984-z.
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.
Wolska-Washer A, Robak T
Front Oncol. 2023; 13:1130595.
PMID: 37035197
PMC: 10076791.
DOI: 10.3389/fonc.2023.1130595.
Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.
Sousa B, de Almeida C, Barahona A, Lopes R, Martins-Logrado A, Cavaco M
ACS Pharmacol Transl Sci. 2022; 5(11):1156-1168.
PMID: 36407952
PMC: 9667546.
DOI: 10.1021/acsptsci.2c00163.
Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice.
Rao H, Song X, Lei J, Lu P, Zhao G, Kang X
Int J Mol Sci. 2022; 23(21).
PMID: 36362264
PMC: 9657648.
DOI: 10.3390/ijms232113478.
Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo.
Ye X, Liu M, Lv C, Li Y, Chen L, Zhang J
Technol Cancer Res Treat. 2022; 21:15330338221133224.
PMID: 36254554
PMC: 9580088.
DOI: 10.1177/15330338221133224.
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect.
Wang H, Guo H, Yang J, Liu Y, Liu X, Zhang Q
Exp Hematol Oncol. 2022; 11(1):60.
PMID: 36138486
PMC: 9493169.
DOI: 10.1186/s40164-022-00315-9.
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
Qualls D, Kumar A, Epstein-Peterson Z
Leuk Lymphoma. 2022; 63(11):2515-2527.
PMID: 35704674
PMC: 9741766.
DOI: 10.1080/10428194.2022.2086244.
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.
Maskalenko N, Zhigarev D, Campbell K
Nat Rev Drug Discov. 2022; 21(8):559-577.
PMID: 35314852
PMC: 10019065.
DOI: 10.1038/s41573-022-00413-7.
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H
Blood. 2022; 139(21):3148-3158.
PMID: 35303070
PMC: 9136878.
DOI: 10.1182/blood.2021014162.
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
Tbakhi B, Reagan P
Ther Adv Hematol. 2022; 13:20406207221080738.
PMID: 35237395
PMC: 8882938.
DOI: 10.1177/20406207221080738.
The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.
Robak T, Witkowska M, Smolewski P
Cancers (Basel). 2022; 14(3).
PMID: 35159041
PMC: 8833747.
DOI: 10.3390/cancers14030771.
Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.
Chu X, Bu Y, Yang X
Front Oncol. 2022; 11:785855.
PMID: 34976824
PMC: 8718447.
DOI: 10.3389/fonc.2021.785855.
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai J, Mato A, Dogan A, Seshan V, Joffe E, Flaherty K
Lancet Haematol. 2021; 8(12):e879-e890.
PMID: 34826411
PMC: 9326222.
DOI: 10.1016/S2352-3026(21)00307-0.
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.
Davis J, Sharpe C, Mason K, Tam C, Koldej R, Ritchie D
J Transl Med. 2021; 19(1):473.
PMID: 34809665
PMC: 8609739.
DOI: 10.1186/s12967-021-03136-2.
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies.
Zhu S, Jung J, Victor E, Arceo J, Gokhale S, Xie P
Front Oncol. 2021; 11:737943.
PMID: 34778053
PMC: 8585514.
DOI: 10.3389/fonc.2021.737943.
